Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02535234
Other study ID # MA011015
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2016
Est. completion date June 2016

Study information

Verified date February 2021
Source ResMed
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomised crossover trial of a novel and traditional Continuous Positive Airway Pressure (CPAP) system in Obstructive Sleep Apnoea patients.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Participant is willing to provide written informed consent - Participant is able to read and comprehend written and spoken English - Participant is = 18 years of age - Participant has been diagnosed with Obstructive Sleep Apnoea (OSA) - Participants has been established on Continuous Positive Airway Pressure (CPAP) for = 6 months - Participants is currently using the same mask type/variant as the interventional mask system to be evaluated - Participants is able to participate for the duration of the study Exclusion Criteria - Participant is not willing to provide written informed consent - Participant is unable to read and comprehend written and spoken English - Participant is < 18 years of age - Participant has not been diagnosed with Obstructive Sleep Apnoea (OSA) - Participant has not been established on Continuous Positive Airway Pressure (CPAP) for = 6 months - Participant is not currently using the same mask type/variant as the interventional mask system to be evaluated - Participant is unable to participate for the duration of the study - Participant is pregnant - Participant is established on bi-level support therapy - Participant, or participants bed partner, has metallic implants in head neck or chest - Participant has a with a pre-existing lung disease or a condition that would predispose them to pneumothorax (e.g. Chronic Obstructive Pulmonary Disease (COPD), lung cancer; fibrosis of the lungs; recent (< 2years) case of pneumonia or lung infection, lung injury) - Participant is unsuitable to participate in the study in the opinion of the researcher

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Novel System
A Novel full Continuous Positive Airway Pressure (CPAP) system - Prototype Device, Mask + Accessories
Traditional System
A Traditional full Continuous Positive Airway Pressure (CPAP) system- Released Device + Accessories, Prototype Mask

Locations

Country Name City State
Australia ResMed Sydney New South Wales

Sponsors (1)

Lead Sponsor Collaborator
ResMed

Country where clinical trial is conducted

Australia, 

References & Publications (3)

Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013 May 1;177(9):1006-14. doi: 10.1093/aje/kws342. Epub 2013 Apr 14. — View Citation

Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993 Apr 29;328(17):1230-5. — View Citation

Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002 May 1;165(9):1217-39. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Subjective usability ratings of the prototype system using a visual analogue scale, compared to a reference level and the second full system. Participants will be asked to complete a short questionnaire at the end of each week to evaluate the general usability of the system. The questionnaire will include questions related to system use and comfort. The participants will answer the questions using an 11-point Likert scale. 1 year
See also
  Status Clinical Trial Phase
Completed NCT01620554 - Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) Phase 2
Not yet recruiting NCT01985347 - The SAD Study - SLEEP, ANXIETY & DEPRESSION Study A Prospective Cohort Study N/A
Completed NCT01312558 - The Effect of the Mediterranean Diet on Obstructive Sleep Apnoea-Hypopnoea Syndrome: A Randomised Trial N/A
Completed NCT02967536 - Investigating the Neuropathology of Obstructive Sleep Apnoea
Completed NCT02855515 - Drug-Induced Sleep Endoscopy for the Optimisation of Treatment of Patients With Obstruction Sleep Apnoea N/A
Terminated NCT03127800 - Morphine in Moderate Obstructive Sleep Apnoea Phase 3
Recruiting NCT04262986 - A Brief Lifestyle Modification Programme in Overweight Subjects With Obstructive Sleep Apnoea - Needs Assessment
Completed NCT03145129 - PAIR Study-PAP And IOP Relationship: Study 2
Completed NCT02713152 - Prevalence of Obstructive Sleep Apnoea in Glaucoma N/A
Completed NCT06376305 - EndoBarrier in Obstructive Sleep Apnoea Study N/A
Completed NCT01661712 - Continuous Transcutaneous Electrical Stimulation in Sleep Apnoea N/A
Terminated NCT01530451 - Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients Phase 3
Completed NCT02518633 - Obstructive Sleep Apnoea and Adipose Tissue Dysfunction N/A
Completed NCT01557166 - Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALEā„¢ - Sleep Apnoea Phase 3
Recruiting NCT01829854 - To Investigate the Incidence of Obstructive Sleep Apnoea in Patient Undergoing Open Heart Surgery N/A
Completed NCT01619748 - Peripheral Vascular Function in Obstructive Sleep Apnoea N/A
Completed NCT02417584 - Efficacy of PAP Therapy on Blood Pressure N/A
Completed NCT04071860 - Developing a Non-contact Sleep Apnoea Detector, Suitable for Home Studies- The Safescan Study
Not yet recruiting NCT04607343 - Clinical Trial of a Rehabilitation Device Based on Electrostimulation for Obstructive Sleep Apnoea N/A
Completed NCT01546792 - Lifestyle Intervention in Obstructive Sleep Apnoea Phase 2/Phase 3